The first day of open registration for the COVID-19 vaccines got off to a wobbly start Tuesday in Pennsylvania after health authorities suspended use of the Johnson & Johnson shot, shorting the state 20,000 doses for the week.
An independent Centers for Disease Control and Prevention review committee is meeting in an emergency session Wednesday to review safety data for the J&J shot after six women, ages 18 to 48, developed blood clotting problems within two weeks of receiving the vaccine.
The pause in using the vaccine forced UPMC and other health care providers to switch to the two-shot Pfizer-BioNTech and Moderna shots at clinics scheduled this week. A drive-up UPMC vaccination clinic at the Galleria at Pittsburgh Mills in Frazer Wednesday and Thursday, where the J&J vaccine was to have been administered, will instead use the Pfizer-BioNTech shot, a spokesman said.
No appointments are necessary at the clinic through 5 p.m. Wednesday and from 8 a.m. to 5 p.m. Thursday.
Nickman’s Fayette County drug stores in Lemont Furnace, Fairchance and Connellsville were planning to switch to the Moderna vaccine for people who’d registered for the J&J shots this week.
Concern over the safety of the J&J shots could increase fears about all COVID-19 vaccines, increasing hesitancy to get inoculated at a time when coronavirus variants are fueling the spread of the disease, said Don Burke, former dean of the University of Pittsburgh’s Graduate School of Public Health and co-founder of Pitt spinout company Epistemix Inc., which models the spread of diseases and social forces within populations.
Read More
“Concern about vaccines in general could potentially spill over into worry about new symptoms and may contribute to hesitancy about the Moderna and Pfizer vaccines, which would not be warranted,” he said. “But it’s an understandable human reaction.”
Still, “one in a million for side effects is not a particularly high rate for a reaction,” Dr. Burke said.
The six women who suffered the reactions were among 6.8 million people who received the J&J vaccine, making the possibility of being harmed about half as likely as being struck by lightning in a year.
More concerning is a highly contagious variant of the coronavirus, which causes COVID-19, which makes the virus 1.5 times faster moving, he said. The B.1.1.7 variant is expected to become the dominant strain in the U.S. in May.
“Overall, the pace of vaccination has been fantastic,” Dr. Burke said, but coronavirus variants like B.1.17 will make it “that much harder to stay ahead of the pandemic,” he said. “The loss of another vaccine will slow down the national response.”
In the U.S., 75.3 million people have been fully vaccinated, which is 22.7% of the population, according to the CDC. As of Tuesday in Allegheny County, 300,702 people were fully vaccinated, or 24.7% of the total population.
State health department acting secretary Alison Beam said the pause in administering the vaccine in Pennsylvania would last at least until April 20. At a briefing Tuesday, Food and Drug Administration acting commissioner Janet Woodcock said she expected the suspension to last a “matter of days.”
Vaccine providers were scheduled to get 270,000 doses of vaccine this week in Pennsylvania, including 20,000 J&J shots, according to the health department.
Among the issues the CDC’s 15-member scientific and medical committee will review is the possibility of similar adverse reactions to the J&J vaccine that have not been widely reported. A vote on whether to endorse continued use of the vaccine is scheduled for Wednesday afternoon.
The committee’s recommendation may come down to assessing the risk of the J&J shot.
No medicine is 100% safe, so giving vaccines must balance risk and benefit, said Paul Offit, a former member of the CDC’s ACIP committee and director of the vaccine education center at Children’s Hospital of Philadelphia. He said the committee was likely to recommend continued use of the J&J vaccine, but perhaps with some restrictions.
He did not expect the committee to recommend banning the vaccine.
“They’re going to move forward in some way with this vaccine,” Dr. Offit said. “Every vaccine has risks. Any medical product can have a risk. This is a study in how to communicate risk.”
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.
This story was originally published with images that are no longer available.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.